JAK-STAT inhibition an attractive target.

ATOPIC dermatitis; BALDNESS; CELLULAR signal transduction; CYTOKINES; GROWTH factors; INFLAMMATION; NEUROTRANSMITTER uptake inhibitors; ORAL drug administration; PATIENT safety; PSORIASIS; SKIN diseases; VITILIGO; JANUS kinases

The article discusses efforts to develop janus kinase-signal transducer and activator of transcription (JAK-STAT) inhibitors for use in dermatology. Topics covered include the use of JAK-STAT inhibitors for the treatment of atopic dermatitis, alopecia areata, vitiligo and psoriasis, and its potential for unwanted consequences such as increased risks of infection and malignancies, mild increases in serum lipids, and the development of certain cytopenias.